TECHNICAL FIELD
The present invention is directed to a novel crystalline form of Eluxadoline, pharmaceutical compositions containing this form, processes for its preparation, and its use in the treatment of opioid-modulated disorders, including irritable bowel syndrome.
BACKGROUND
The compound